DA Davidson maintains PaySign at Buy, lowers price target to $14 from $15

DA Davidson kept PaySign's rating at Buy but reduced its price target from $15 to $14, a 6.7% cut. This implies a 38.1% upside from the Nov 10 close of $10.14, according to the firm.

Original reporting
Published Nov 11, 2026, 6:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 6:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DA Davidson maintains PaySign at Buy, lowers price target to $14 from $15 — source image
Decision brief

The 30-second read

Low
01

Why it matters

Analyst rating change provides modest guidance signal but lacks material catalyst.

02

Market read

Small‑cap rating update with limited trading impact.

03

What to watch

No new fundamental data; only analyst opinion shift.

Relevance 5/10Novelty 5/10Timing: today

Background

DA Davidson lowered its price target for PaySign from $15 to $14, maintaining a Buy rating.

Market effects

minimal impact on payment processing sector

none

low

Counterpoint

Target reduction may be overly cautious; price could still rise on broader fintech rally.

Key entities

  • PaySign

    Fintech firm providing payment solutions.

  • DA Davidson

    Equity research firm issuing the rating.

Related articles

$PAYSMedAI 8/10

Paysign (PAYS) Q3 2026 Earnings Call Transcript

Paysign (PAYS) reported Q3 2026 earnings, highlighting growth in its patient affordability business with revenue doubling to $16.6M YoY. Plasma revenue rose 7.5% to $13.8M. The company expects to offset a loss of 113 plasma centers with new clients. Patient affordability drove strong margins and operating leverage, while Apherion, a plasma industry software, is under regulatory review.

$PAYSHigh

Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8%

Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Earnings Release Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8% Patient Affordability Growth Drives Revenue and Margin Expansion Raises Full Year 2026 Gross Margin, Net Income, GAAP EPS and Adju

$PAYSHigh

Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook

Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Earnings Release Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook Growth Driven by Continued Momentum in Plasma and Patient Affordability Businesses Mix Shift and Expense Discipline Continue to Drive Gross and Oper

$NVDAHigh

Forget Former Nvidia CEO Jensen Huang -- This Is the Real Question Investors Need to Ask About Nvidia Stock

Nvidia's (NVDA) CEO Jensen Huang resigned following reports of alleged extramarital affairs. CFO Colette Kress is interim CEO. NVDA stock fell 28% in a month. Questions arise about Nvidia's revenue from alleged illegal chip sales to China via Singaporean data center Megaspeed, with short-seller Culper Research claiming 20% of FY 2026 compute revenues may have been diverted. Nvidia denies these claims, but the situation could impact future sales and export restrictions.

$MRNAMed

Moderna Sinks 12% in a Week. Bancel Wants an FDA Filing “Before the End of the Year”

Moderna (MRNA) fell 12% in the week to Nov. 13 after projecting $4B+ annual costs through 2030, primarily for cancer drug development, including intismeran with Merck (MRK). CEO Bancel aims for FDA filing by year-end. Analysts' 2028 revenue estimates are below annual costs, and the stock trades at a high sales multiple. BioNTech (BNTX), a rival, expects revenue to fall 35.4% this year.